Singapore · Regenerative Medicine Platform
Because
In every
Cell lies a
Cure.
BICC is a Singapore-based regenerative medicine platform advancing Extracellular Vesicle science — structured across three complementary pillars, and self-sustained by its own profitable health and infrastructure businesses.
1 in 3
Asians will be over 60 by 2050 — Source: UN
$150B+
Global regenerative medicine market by 2030 · CAGR ~23–25%
$40–55B
Asia-Pacific TAM by 2030, growing to $160–220B by 2050
~15%
Net margin — already profitable · 2025E group revenue $6.2M
The Problem
Asia is Ageing Faster Than
Medicine Can Keep Up.
By 2050, one in three Asians will be over 60 — a demographic shift with no historical precedent. Chronic disease, metabolic decline and neurodegenerative conditions are straining individuals and health systems. Conventional medicine manages symptoms.
Asia needs a regenerative, preventive answer — built at the cellular level. BICC was founded to close the gap between how long people live and how long they live well.
The Model
Three Pillars.
One Self-Sustaining Platform.
Most biotech companies burn capital while waiting for science to become revenue. BICC is structured differently.
Why BICC
Science That Pays for Itself.
Built to Scale.
Most regenerative medicine companies are entirely dependent on external funding to sustain their research. BICC is structured differently — our health services and infrastructure businesses generate operating revenue today, funding the EV science platform without diluting the mission or the timeline.
The result is a platform that can move at the pace of science, not the pace of fundraising — advancing Extracellular Vesicle technology from cosmeceuticals to clinical applications, anchored by a signed Research Collaboration Agreement with A*STAR, Singapore's national research agency.